Table S1. Clinical characteristics according to groups.

	Moderate CV Risk (n= 172, 29.3%)	**High CV Risk (n= 306, 52%)**	**Very High CV Risk (n= 73, 12.4%)**	**Extreme CV Risk (n= 37, 6.3%)**	**Overall (n= 588)**	**p**
Demographic/anthropometric and Clinical characteristics						
Age (yrs)	56 [53-59.8]	61 [58-64]	67 [63-74]	64 [60-67]	60 [56-64]	**p < 0.0001**
BMI (kg/m^2)	24.2 [21.9-26.2]	24.9 [22.3-28.3]	24.3 [22.8-27.9]	23.7 [20.8-29.2]	24.5 [22.1-27.8]	p = 0.110
Male	101 (58.7%)	232 (75.8%)	56 (76.7%)	33 (89.2%)	422 (71.8%)	**p < 0.0001**
Diabetes	16 (9.3%)	42 (13.7%)	23 (31.5%)	14 (37.8%)	95 (16.2%)	**p < 0.0001**
Hypertension	41 (23.8%)	105 (34.3%)	34 (46.6%)	19 (51.4%)	199 (33.8%)	**p < 0.0001**
Current Smoking	23 (13.9)	88 (31.7)	31 (44.8)	14 (38.9)	156 (28.5%)	**p < 0.0001**
Waist circumference (cm)	90 [82-97]	95 [84.5-105]	96 [88.5-101.5]	90.5 [81.3-106.3]	92.5 [85-102]	**p < 0.0001**
Waist/Height ratio	0.53 [0.48-0.57]	0.55 [0.5-0.6]	0.57 [0.52-0.61]	0.54 [0.5-0.64]	0.54 [0.49-0.6]	**p < 0.0001**
HIV infection related characteristics						
Time since HIV diagnosis	27 [23-35]	29 [18-35]	31 [27-36]	32 [24-36]	29 [22-35]	**p = 0.003**
Nadir CD 4 (cells/mL)	263 [128-317.5]	161 [55-304]	167 [46.8-360.8]	225 [23.8-297.5]	200 [80-300]	p= 0.195
CD4 absolute cells count (cells/mL)	694 [537-802.5]	657 [512-810]	654 [503-936.3]	785.5 [616.8-989]	743 [550-954]	p = 0.627
CD4/CD8	0.91 [0.6-1.5]	0.83 [0.55-1.43]	0.88 [0.53-1.59]	0.94 [0.73-1.18]	0.92 [0.65-1.43]	p = 0.738
HIV undetectable	169 (98.3%)	295 (96.4%)	72 (98.6%)	37 (100%)	573 (97.4%)	p = 0.366
Antiretroviral therapy at baseline						
Current exposure to NRTI	106 (61.6%)	166 (54.2%)	48 (65.8%)	26 (70.3%)	346 (58.8%)	p = 0.084
Current exposure to PI	12 (7%)	32 (10.5%)	9 (12.3%)	5 (13.5%)	58 (9.9%)	p = 0.426
Current exposure to NNRTI	73 (42.4%)	112 (36.6%)	18 (24.7%)	10 (27%)	213 (36.2%)	**p = 0.034**
Current exposure to INSTI	122 (70.9%)	216 (70.6%)	56 (76.7%)	33 (89.2%)	427 (72.6%)	p = 0.086
Antiretroviral therapy at follow-up						
Current exposure to NRTI	108 (62.8%)	172 (56.2%)	50 (68.5%)	27 (73%)	357 (60.7%)	p = 0.069
Current exposure to PI	13 (7.6%)	25 (8.2%)	7 (9.6%)	2 (5.4%)	47 (8%)	p = 0.886
Current exposure to NNRTI	67 (39%)	112 (36.6%)	19 (26%)	11 (29.7%)	209 (35.5%)	p = 0.216

Current exposure to INSTI	125 (72.5%)	221 (72.2%)	58 (79.5%)	35 (94.6%)	439 (74.7%)	**p = 0.019**

ASMI= appendicular skeletal muscle mass index, BMI=body mass index, BSA= body surface area, INSTI= Integrase Strand Transfer Inhibitors, NRTI= Nucleoside Reverse Transcriptase Inhibitors, NNRTI= Non-Nucleoside Reverse Transcriptase Inhibitors, PI= protease inhibitor. Tenofovir disoproxil fumarate was used only in combination with doravirine plus lamivudine, otherwise tenofovir alafenamide was used.

Table S2. Dyslipidemia laboratory data and treatment characteristics between groups.

	Moderate CV Risk (n= 172)	**High CV Risk (n= 306)**	**Very High CV Risk (n= 73)**	**Extreme CV Risk (n= 37)**	**Overall (n= 588)**	**p**
Primary prevention	172 (100%)	306 (100%)	58 (79.5%)	0	536 (91.2%)	**p < 0.0001**
Baseline HDL (mg/dL)	57 [47-68.8]	48 [42-57]	45 [40-57]	44 [37.5-54]	50 [43-60]	**p < 0.0001**
Baseline LDL (mg/dL)	113.5 [92.3-133.8]	105 [80-135]	99.5 [77.8-124.6]	76 [66-105.5]	106 [82.3-133]	**p < 0.0001**
Baseline Total cholesterol (mg/dL)	185.5 [161-226.8]	174 [135.8-212.3]	167.5 [133.5-196.3]	133 [112.5-174]	176 [140-208]	**p < 0.0001**
Follow-up HDL (mg/dL)	58 [45-68]	48 [42-58]	45 [40-57]	44 [37.5-54]	50 [42-60]	**p < 0.0001**
Follow-up LDL (mg/dL)	104 [81-131]	95.5 [71-119]	99.5 [77.8-124.3]	76 [66-105.5]	96 [71.3-120]	**p < 0.0001**
Follow-up Total cholesterol (mg/dL)	175 [142.3-205]	157 [124-189]	155.5 [116-177]	129 [104.5-153.5]	159 [128-190]	**p < 0.0001**
LDL on target at baseline	54 (31.4%)	50 (16.3%)	6 (8.2%)	5 (13.5%)	115 (19.6%)	**p < 0.0001**
LDL on target at follow-up	80 (46.5%)	70 (22.9%)	11 (15.1%)	8 (21.6%)	169 (28.7%)	**p < 0.0001**
LDL variation	3.2% [-7.9;19]	5.3% [-7.5;22]	1% [-9;20.2]	7.5% [-2.9;23.8]	3.6% [-7.2;21.4]	p = 0.673
Lipid lowering therapy at the time of first clinical evaluation						
Statins	52 (30.2%)	159 (52%)	44 (60.3%)	28 (75.7%)	283 (48.1%)	**p < 0.0001**
• High intensity statins	13 (24.5%)	43 (26.7%)	18 (40%)	21 (72.4%)	95 (33%)	**p < 0.0001**
• Moderate intensity statins	37 (69.8%)	112 (69.6%)	24 (53.3%)	6 (20.7%)	179 (62.2%)	**p < 0.0001**
• Low intensity statins	2 (3.8%)	3 (1.9%)	2 (4.4%)	1 (3.4%)	8 (2.8%)	p = 0.568
Atorvastatin	23 (13.4%)	67 (21.9%)	25 (34.2%)	12 (32.4%)	127 (21.6%)	**p = 0.001**
Rosuvastatin	27 (15.7%)	90 (29.4%)	18 (24.7%)	16 (43.2%)	151 (25.7%)	**p = 0.001**
Bempedoic Acid	1 (0.6%)	5 (1.6%)	2 (2.7%)	3 (8.1%)	11 (1.9%)	**p = 0.078**
Ezetimibe	23 (13.4%)	72 (23.5%)	20 (27.4%)	19 (51.4%)	134 (22.8%)	**p < 0.0001**
Evolocumab	0	3 (1%)	2 (2.7%)	3 (8.1%)	8 (1.4%)	**p = 0.008**
Single lipid lowering agent	34 (19.8%)	113 (36.9%)	35 (47.9%)	16 (43.2%)	198 (33.7%)	**p < 0.0001**
Two lipid lowering agents	21 (12.2%)	59 (19.3%)	15 (20.5%)	14 (37.8%)	109 (33.7%)	**p = 0.005**
Three lipid lowering agents	0	3 (1%)	1 (1.4%)	3 (8.4%)	7 (1.2%)	**p = 0.013**
Statin and Ezetimibe	20 (11.6%)	59 (19.3%)	15 (20.5%)	16 (43.2%)	110 (18.7%)	**p < 0.0001**

Statin and Bempedoic Acid plus Ezetimibe	0	3 (1%)	1 (1.4%)	2 (5.4%)	6 (1%)	p = 0.068
Statin and Bempedoic Acid	0	3 (1%)	1 (1.4%)	2 (5.4%)	6 (1%)	p = 0.068
Bempedoic Acid and Ezetimibe	1 (0.6%)	5 (1.6%)	2 (2.7%)	3 (8.1%)	11 (1.9%)	p = 0.078
Evolocumab and other lipid lowering agents	0	1 (0.3%)	1 (1.4%)	1 (2.7%)	3 (0.5%)	p = 0.217
Lipid lowering therapy at the time of last clinical evaluation						
Statins dose escalation	3 (1.7%)	9 (2.9%)	3 (4.1%)	2 (5.4%)	17 (2.9%)	p = 0.567
New LLT prescription	27 (15.7%)	36 (11.8%)	6 (8.2%)	0	69 (11.7)	p = 0.059
Statins • High intensity statins • Moderate intensity statins • Low intensity statins	72 (41.9%) 20 (27.8%) 50 (69.4%) 2 (2.8%)	189 (61.8%) 58 (30.7%) 127 (67.2%) 4 (2.1%)	47 (64.4%) 22 (46.8%) 25 (53.2%) 0	30 (80.1%) 25 (83.3%) 3 (10%) 2 (6.7%)	338 (57.5%) 125 (34%) 205 (60.7%) 8 (2.4%)	**p < 0.0001** **p < 0.0001** **p < 0.0001** p = 0.742
Atorvastatin	29 (16.9%)	71 (23.2%)	25 (34.2%)	12 (32.4%)	138 (23.5%)	**p = 0.001**
Rosuvastatin	41 (23.8%)	118 (38.6%)	18 (24.7%)	16 (43.2%)	197 (33.5%)	**p = 0.001**
Bempedoic Acid	6 (3.5%)	19 (6.2%)	2 (2.7%)	3 (8.1%)	37 (6.3%)	**p = 0.020**
Ezetimibe	45 (26.2%)	113 (36.9%)	20 (27.4%)	19 (51.4%)	212 (36.1%)	**p < 0.0001**
Evolocumab	1 (0.6%)	4 (1.3%)	2 (2.7%)	3 (8.1%)	11 (1.9%)	**p = 0.020**
Single lipid lowering agent	40 (23.3%)	102 (33.3%)	35 (47.9%)	16 (43.2%)	182 (31%)	**p = 0.041**
Two lipid lowering agents	39 (22.7%)	92 (30.1%)	26 (35.6%)	18 (48.6%)	175 (29.8%)	**p = 0.009**
Three lipid lowering agents	2 (1.2%)	13 (4.2%)	2 (2.7%)	5 (13.5%)	22 (3.7%)	**p = 0.004**
Combination LLT	41 (23.8%)	105 (34.3%)	28 (38.4%)	23 (62.2%)	197 (33.5%)	**p < 0.0001**
Combination LLT new	12 (7%)	36 (11.8%)	15 (20.5%)	8 (21.6%)	71 (12.1%)	**p = 0.008**
Statin and Ezetimibe	38 (22.1%)	98 (32%)	15 (20.5%)	16 (43.2%)	181 (30.8%)	**p < 0.0001**
Statin and Bempedoic Acid plus Ezetimibe	2 (1.2%)	12 (3.9%)	1 (1.4%)	2 (5.4%)	20 (3.4%)	**p = 0.031**
Statin and Bempedoic Acid	2 (1.2%)	11 (3.6%)	1 (1.4%)	2 (5.4%)	19 (3.2%)	p = 0.031
Bempedoic Acid and Ezetimibe	6 (3.5%)	18 (5.9%)	2 (2.7%)	3 (8.1%)	36 (6.1%)	**p = 0.020**
Evolocumab and other lipid lowering agents	6 (3.5%)	19 (6.2%)	1 (1.4%)	1 (2.7%)	37 (6.3%)	p = 0.130

Combination LLT refers to PWH treated with either two or three LLT; Combination LLT new refers to PWH that were not on LLT combination regimens at baseline and were on combination LLT at the time of last clinical evaluation; LDL variation = ((LDL baseline-LDL follow-up)/LDL baseline)*100.